English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background   Pseudomonas aeruginosa  has recently shown to be one of the most important strains of bacteria and alert pathogens in Europe among Intensive Care Unit patients that provide serious therapeutic problems because of its multidrug resistance.    Methods  The purpose of this microbiological study was data analysis of device associated- healthcare associated infections (DA-HAIs) in an ICU in terms of the incidents of  P.aeruginosa  strain infections and its susceptibility within an 8.5-year observation.    Results  Among 919 isolated strains responsible for 799 DA-HAIs (17,62 ± 1,98/1000 patient-days) in 4010 ICU patients  P.aeruginosa  was the pathogen in 108/799 (13.52%) cases. Incidence rate (density) of: VAP/1000 MV- days, UTI /1000 UC- days and CLA-BSI/1000 CL- days were 11,15 ± 2.5, 6.82 ± 0.81, 2.35 ± 1.54.respectivelly.  P.aeruginosa  was the pathogen most frequently responsible for VAP 69/108 (63.88%). Mean frequency of VAP, UTI and CLA-BSI with  P.aeruginosa  etiology was 69/493 (14.28%), 32/299 (11.1%) and 7/127 (5.77%) respectively. The mean density of  P.aeruginosa  infection amounted to 2.43/1000 patient-days. The decrease was observed in the total number of DA-HAIs caused by the  P.aeruginosa  from 15.75% and 3.23/1000 patient-days in 2011 to 5.0% and 1.17/1000 in 2016 ( p  = 0.0104,  p  = 0.0348). Starting from 2016 to 2019 incidence and density of  P.aeruginosa  DA-HAIs increased to 12.33% and 2.63/1000 ( p  = 0.1388,  p  = 0.0818).  P.aeruginosa  was susceptible to ceftazidime, cefepime, amikacin, meropenem, ciprofloxacin, colistin, in 55.55, 58.33, 70.37, 53.73, 50, and 100% respectively. MDR characterised it in 40% in 2011 and 66.7% in 2019, ( p  = 0.177).    Conclusions  The study revealed a changeable prevalence of  P. aeruginosa  strain infections; however their frequency was never highest in our ICU patients as it presented in the last years in Europe. The study showed a significant decrease in 2016 and increase in 2019, a nearly 3-fold increase of  P.aeruginosa  infections among Gram-negative strain infections, and a 2-fold increase of the  P.aeruginosa  DA-HAIs frequency between 2016 and 2019 as well as an increased resistance. Microbiological analysis of DA-HAIs in each hospital should be a standard method used in hospital infection control and antibiotic policy. In the case of  P.aeruginosa,  in order to minimize transmission, preventive infection methods should be assessed mainly in case of VAP.

bmc infectious diseases

Pseudomonas aeruginosa device associated – healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: polish, 8.5-year, prospective, single-centre study